Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab (BMS-986213) in Advanced Gastric Cancer
NCT03704077Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 14
01
Overview
A Phase 2 trial of relatlimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Bristol Myers Squibb. Planned start Oct 2019; status: withdrawn.
02
Drugs
relatlimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03704077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03704077.